Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics
Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics
复制标题
索磷布韦联合利巴韦林治疗具有不利预处理特征的基因 1 型丙型肝炎是安全有效的
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
McKenzie C. Ferguson
中科院分区：
文献类型：
--
作者：
McKenzie C. Ferguson
评论：Osinini A，Meissner EG，Lee YJ，et al. Sofosbuvir和利巴韦林用于具有不利治疗特征的患者的丙型肝炎基因型1：一项随机临床试验。JAMA 2013;310：804-11. [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science]
与聚乙二醇干扰素和利巴韦林（RBV）治疗相比，新的直接作用型抗病毒治疗改善了丙型肝炎病毒（HCV）的治疗，从而提高了持续病毒学应答（SVR）率。1，2尽管有这些改善，但当不使用干扰素治疗时，直接作用型药物与耐药性有关。该指南建议将其与聚乙二醇干扰素α和RBV联合使用作为HCV基因型1.1，2的最佳治疗方法。然而，这增加了药物治疗方案的复杂性，可能导致不良反应和药物相互作用的可能性。
[1]：{openurl}？query= rft.jtitle%253DJAMA%26rft.volume%253D310%26rft.spage%253D804%26rft_id%253Dinfo%253Dinfo%253Aofi%252F10.1001%252Fjama.2013.109309%26rft_id%253Dinfo%253Apmid%252F23982366%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx % 253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx
[2]：/lookup/external-ref？access_num=10.1001/jama.2013.109309&link_type=DOI
[3]：/lookup/external-ref？access_num=23982366&link_type=MED&atom=%2Febmed%2F19%2F3%2F90.atom
[4]：/lookup/external-ref？access_num=000323561400020&link_type=ISI
Commentary on: Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavourable treatment characteristics: a randomised clinical trial. JAMA 2013;310:804–11.[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4]
Treatment of hepatitis C virus (HCV) has improved with new direct-acting antiviral therapies, resulting in improved sustained virological response (SVR) rates, as compared with the treatment with pegylated interferon and ribavirin (RBV).1 ,2 Despite these improvements, direct-acting agents have been linked to resistance when used without interferon therapy. The guidelines recommend their use in combination with peginterferon α and RBV as optimal therapy in HCV genotype 1.1 ,2 However, this addition adds complexity to the medication regimen, potentially causing adverse effects and potential for drug interactions.2 The aim of this phase 2 study …
[1]: {openurl}?query=rft.jtitle%253DJAMA%26rft.volume%253D310%26rft.spage%253D804%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.2013.109309%26rft_id%253Dinfo%253Apmid%252F23982366%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx
[2]: /lookup/external-ref?access_num=10.1001/jama.2013.109309&link_type=DOI
[3]: /lookup/external-ref?access_num=23982366&link_type=MED&atom=%2Febmed%2F19%2F3%2F90.atom
[4]: /lookup/external-ref?access_num=000323561400020&link_type=ISI
影响因子：
120.7
作者：
Osinusi, Anuoluwapo;Meissner, Eric G.;Lee, Yu-Jin;Bon, Dimitra;Heytens, Laura;Nelson, Amy;Sneller, Michael;Kohli, Anita;Barrett, Lisa;Proschan, Michael;Herrmann, Eva;Shivakumar, Bhavana;Gu, Wenjuan;Kwan, Richard;Teferi, Geb;Talwani, Rohit;Silk, Rachel;Kotb, Colleen;Wroblewski, Susan;Fishbein, Dawn;Dewar, Robin;Highbarger, Helene;Zhang, Xiao;Kleiner, David;Wood, Brad J.;Chavez, Jose;Symonds, William T.;Subramanian, Mani;McHutchison, John;Polis, Michael A.;Fauci, Anthony S.;Masur, Henry;Kottilil, Shyamasundaran
通讯作者：
Kottilil, Shyamasundaran